EGFR and non-small cell lung carcinoma: Meanwhile, males had a greater prevalence of EGFR TP53 comutations in HR- NSCLC compared to HR+ NSCLC (91/134, 67.91% vs. 15/33, 45.45%, p = 0.0254, q= 0.0762).